PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 10:53:31 2024-06-17 EDT | ||
| 3.81 EUR | +1.06% |
|
| 3 months | +37.59% | ||
| 6 months | +34.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 3.81 | +1.06% |
| 24-06-14 | 3.77 | +0.27% |
| 24-06-13 | 3.76 | +3.87% |
| 24-06-12 | 3.62 | -0.55% |
| 24-06-11 | 3.64 | -1.36% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 10:53 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9JAH |
| ISIN | DE000VX9JAH2 |
| Date issued | 2022-04-04 |
| Strike | 81.96 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.86 € |
|---|---|
| Lowest since issue | 0.26 € |
| Spread | 0.01 € |
| Spread % | 0.26% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
